Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 184

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Efficacy of Biological-Targeted Treatments in Takayasu Arteritis: Multicenter, Retrospective Study of 49 Patients

Open access
Mekinian, Arsene, Comarmond, Cloé, Resche-Rigon, Mathieu, Mirault, Tristan, Kahn, Jean Emmanuel, Lambert, Marc, Sibilia, Jean, Néel, Antoine, Cohen, Pascal, Hie, Miguel, Berthier, Sabine, Marie, Isabelle, Lavigne, Christian, Anne Vandenhende, Marie, Muller, Géraldine, Amoura, Zahir, Devilliers, Hervé, Abad, Sébastien, Hamidou, Mohamed, Guillevin, Loïc, Dhote, Robin, Godeau, Bertrand, Messas, Emmanuel, Cacoub, Patrice, Fain, Olivier, Saadoun, David·2015·Circulation

Abstract

Background—: The goal of this work was to assess the safety and efficacy of biologics (ie, tumor necrosis factor-α antagonists and tocilizumab) in patients with Takayasu arteritis. Methods and Results—: This was a retrospective, multicenter study of the characteristics and outcomes of 49 patients with Takayasu arteritis (80% female; median age, 42 years [20–55 years] treated by tumor necrosis factor-α antagonists [80%] or tocilizumab [20%]) and fulfilling American College of Rheumatology or Ishikawa criteria. Factors associated with complete response were assessed. Eighty-eight percent of patients with Takayasu arteritis were inadequately controlled with or were intolerant to conventional immunosuppressive therapy (median number, 3 [1–5]). Overall response (ie, complete and partial) to biological-targeted treatments at 6 and 12 months was 75% and 83%, respectively. There were significantly lower C-reactive protein levels at the initiation of biological-targeted treatments (22 mg/L [10–46 mg/L] versus 58 mg/L [26–76 mg/L]; P =0.006) and a trend toward fewer immunosuppressants drugs used before biologics ( P =0.054) in responders (ie, complete or partial responders) relative to nonresponders to biological-targeted treatments. C-reactive protein levels and daily prednisone dose significantly decreased after 12 months of biological-targeted treatments (30 versus 6 mg/L [ P <0.05] and 15 versus 7.5 mg [ P <0.05] at baseline and 12 months, respectively). The 3-year relapse-free survival was 90.9% (83.5%–99%) over the biological treatment period compared with 58.7% (43.3%–79.7%; P =0.0025) with disease-modifying antirheumatic drugs. No difference in efficacy was found between tumor necrosis factor-α antagonists and tocilizumab. After a median follow-up of 24 months (2–95 months), 21% of patients experienced adverse effects, with biological-targeted treatments discontinued in 6.6% of cases. Conclusion—: This nationwide study shows a high efficacy of biological-targeted treatments in refractory patients with Takayasu arteritis with an acceptable safety profile.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/circulationaha.114.014321

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 184

Metadata

Authors
Mekinian, A., Comarmond, C., Resche-Rigon, M., Mirault, T., Kahn, J. E., Lambert, M., Sibilia, J., Néel, A., Cohen, P., Hie, M., Berthier, S., Marie, I., Lavigne, C., Anne Vandenhende, M., Muller, G., Amoura, Z., Devilliers, H., Abad, S., Hamidou, M., Guillevin, L., Dhote, R., Godeau, B., Messas, E., Cacoub, P., Fain, O., & Saadoun, D.
Venue
Circulation
Published
2015-11-03
Volume
132
Issue
18
Pages
1693-1700
ISSN
  • 0009-7322 (ISSN-L)
  • 1524-4539
OpenAlex
W1895630839
Cited by
184
References
2
FWCI
14.98
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy of Biological-Targeted Treatments in Takayasu Arteritis: Multicenter, Retrospective Study of 49 Patients. https://app.cochat.ai/papers/10.1161/circulationaha.114.014321
The paper
Mekinian, A., Comarmond, C., Resche-Rigon, M., Mirault, T., Kahn, J. E., Lambert, M., Sibilia, J., Néel, A., Cohen, P., Hie, M., Berthier, S., Marie, I., Lavigne, C., Anne Vandenhende, M., Muller, G., Amoura, Z., Devilliers, H., Abad, S., Hamidou, M., . . . Saadoun, D. (2015). Efficacy of Biological-Targeted Treatments in Takayasu Arteritis: Multicenter, Retrospective Study of 49 Patients. Circulation. https://doi.org/10.1161/circulationaha.114.014321

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.